Alector Reports Fourth Quarter and Full Year 2021 Financial Results
February 24, 2022 16:05 ET
|
Alector, Inc.
CTAD and SITC presentations in fourth quarter highlight progress across immuno-neurology and immuno-oncology portfolio Over $900 million in pro forma cash, cash equivalents and investments supports...
Alector Announces Appointment of Marc Grasso, M.D., as Chief Financial Officer
February 07, 2022 08:30 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology...
Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules
January 03, 2022 16:30 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the compensation...
Alector Announces Appointment of Sara Kenkare-Mitra, Ph.D., as President and Head of Research and Development
December 15, 2021 08:30 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of...
Alector Presents Encouraging New AL001 Data from the Symptomatic FTD-GRN Cohort of INFRONT-2 Phase 2 Open-label Clinical Study
November 12, 2021 13:50 ET
|
Alector, Inc.
Progranulin Levels Increase to Normal Ranges Multiple Biomarkers of Disease Showed Improvement from Baseline with AL001 Treatment, Including GFAP, a Prognostic Marker for FTD Associated with Brain...
Alector Presents Preclinical Data from AL009 Multi-Siglec Inhibitor Program at the Society for Immunotherapy of Cancer’s 36th Annual Meeting
November 12, 2021 07:00 ET
|
Alector, Inc.
Preclinical Oncology Program Highlights Alector’s Expertise in Harnessing Components of the Innate Immune System to Impact Disease AL009 Targets Innate Immune Checkpoint Receptors, Blocks Immune...
Alector Presents New Data from Multiple Pipeline Programs at 2021 CTAD Conference
November 10, 2021 08:30 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, shared data from its AL003 and AL101...
Alector to Present at the Stifel 2021 Virtual Healthcare Conference
November 08, 2021 16:05 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Arnon Rosenthal,...
Alector Reports Third Quarter 2021 Financial Results
November 04, 2021 16:05 ET
|
Alector, Inc.
Initiated Phase 2 Clinical Trial of AL001 for the Treatment of Amyotrophic Lateral Sclerosis Executed a Global Collaboration with GSK to Co-development and Co-commercialize Alector’s Progranulin...
Alector to Present New Data from Multiple Pipeline Programs at 2021 CTAD Conference and SITC Annual Meeting
November 03, 2021 16:50 ET
|
Alector, Inc.
Company to Host Analyst and Investor Conference Call on November 12 at 4:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage...